Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "ABB"

439 News Found

AbbVie submits Biologics license application to USFDA for Telisotuzumab Vedotin
Drug Approval | September 28, 2024

AbbVie submits Biologics license application to USFDA for Telisotuzumab Vedotin

Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression


Sightsavers India and AbbVie India host consultation on Glaucoma prevention in Bhopal
Healthcare | September 23, 2024

Sightsavers India and AbbVie India host consultation on Glaucoma prevention in Bhopal

The objectives of the campaign are to raise awareness about glaucoma, its risk factors, and the importance of regular eye check-up


Abbott India inks non-exclusive patent license agreement with Takeda for Vonoprazan
News | September 20, 2024

Abbott India inks non-exclusive patent license agreement with Takeda for Vonoprazan

This license will enable Abbott to enhance access to this novel therapy to more patients across India


Ashland Rad-Sure indicators approved by AABB Standards-Compliant product program
News | August 21, 2024

Ashland Rad-Sure indicators approved by AABB Standards-Compliant product program

Rad-Sure blood irradiation indicators are FDA 510 (k) cleared medical devices that offer positive visual verification of irradiation at the minimum specified dose


AbbVie completes acquisition of Cerevel Therapeutics
News | August 03, 2024

AbbVie completes acquisition of Cerevel Therapeutics

Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia


AbbVie appoints Roopal Thakkar as EVP, Research & Development and Chief Scientific Officer
People | July 10, 2024

AbbVie appoints Roopal Thakkar as EVP, Research & Development and Chief Scientific Officer

Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program


Abbott and YRGCARE inaugurate new outreach centers in India
News | July 02, 2024

Abbott and YRGCARE inaugurate new outreach centers in India

Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases


AbbVie appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors
People | June 22, 2024

AbbVie appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors

Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director


Abbott wins CE mark for dual-chamber leadless pacemaker
News | June 11, 2024

Abbott wins CE mark for dual-chamber leadless pacemaker

Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers


AbbVie announces positive results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine for high FR? expressing platinum-sensitive ovarian cancer
Clinical Trials | June 07, 2024

AbbVie announces positive results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine for high FR? expressing platinum-sensitive ovarian cancer

PICCOLO trial met its primary endpoint of objective response rate (ORR)